Effect of sildenafil on proliferation of human lymphatic malformations endothelial cells

Abstract

Abstract: PURPOSE: To explore the effect and mechanism of sildenafil on proliferation of human lymphatic malformations endothelial cells (HLMECs) in vitro. METHODS: Tissue block culture method was used to culture HLMECs in vitro, which were identified by immunocytochemistry (CD31 and LYVE-1). Subsequent studies were performed using third-generation cells, the cells were treated with sildenafil at the concentration of 1, 2, 5 and 10 μmol/L, respectively, cell morphology was observed under an inverted microscope; cell proliferation activity was detected by MTT and EDU staining, and the expression level of vascular endothelium growth factor C (VEGFC) and its receptor VEGFR-3 was detected by Western blot. Independent-samples t test and ANOVA (LSD method) were performed using SPSS 21.0 software package for statistical analysis. RESULTS: Cells cultured by tissue block method revealed both positive CD31 and LYVE-1 staining. After treated with sildenafil, the cell morphology was changed and the density of the cells was decreased. MTT and EDU staining reflected that the cell proliferation was significantly inhibited by sildenafil at the concentration of 2 μmol/L (P<0.05). There was also decreased level of VEGFC and VEGFR-3, detected by Western blot. CONCLUSIONS: Sildenafil could inhibit the proliferation of HLMECs in vitro. The mechanism might be relate to the regulation of VEGFC /VEGFR-3.

Key words: Sildenafil, Lymphatic malformation, Endothelial cells

CLC Number:

null

NING Jie-xin, HUANG Ying-ying, WANG Yi-fei, DONG Jian-yong, CAO Yi, LIU Shao-hua. Effect of sildenafil on proliferation of human lymphatic malformations endothelial cells[J]. China Journal of Oral and Maxillofacial Surgery, 2017, 15(4): 289-294.

References

[1] Hassanein AH, Mulliken JB, Fishman SJ, et al. Lymphatic malformation: risk of progression during childhood and adolescence [J]. J Craniofac Surg, 2012, 23(1): 149-152.
[2] Bagrodia N, Defnet AM, Kandel JJ. Management of lymphatic malformations in children [J]. Curr Opin Pediatr, 2015, 27(3): 356-363.
[3] Swetman GL, Berk DR, Vasanawala SS, et al. Sildenafil for severe lymphatic malformations [J]. N Engl J Med, 2012, 366(4): 384-386.
[4] Koshy JC, Eisemann BS, Agrawal N, et al. Sildenafil for microcystic lymphatic malformations of the head and neck: A prospective study [J]. Int J Pediatr Otorhinolaryngol, 2015, 79(7): 980-982.
[5] George R, Shah R, Bulas D, et al. The delivered promise of prenatal imaging and a challenge to the utility of sildenafil for severe lymphatic malformations [J]. Int J Pediatr Otorhinolaryngol, 2015, 79(2): 89-93.
[6] Horbach SE, Jolink F, van der Horst CM. Oral sildenafil as a treatment option for lymphatic malformations in PIK3CA-related tissue overgrowth syndromes [J]. Dermatol Ther, 2016, 29(6): 466-469.
[7] Danial C, Tichy AL, Tariq U, et al. An open-label study to evaluate sildenafil for the treatment of lymphatic malformations [J]. J Am Acad Dermatol, 2014, 70(6): 1050-1057.
[8] Gandhi NG, Lin LK, O'Hara M. Sildenafil for pediatric orbitallymphangioma [J]. JAMA Ophthalmol, 2013, 131(9): 1228-1230.
[9] Perkins JA, Manning SC, Tempero RM, et al. Lymphatic malformations: current cellular and clinical investigations [J]. Otolaryngol Head Neck Surg, 2010, 142(6): 789-794.
[10] Lokmic Z, Mitchell GM, Koh Wee Chong N, et al. Isolation of human lymphatic malformation endothelial cells, their in vitro characterization and in vivo survival in a mouse xenograft model [J]. Angiogenesis, 2014, 17(1): 1-15.
[11] You L, Wu M, Chen Y, et al. Isolation and characterization of lymphatic endothelial cells from human glossal lymphangioma [J]. Oncol Rep, 2010, 23(1): 105-111.
[12] Boscolo E, Coma S, Luks VL, et al. AKT hyper-phosphorylation associated with PI3K mutations in lymphatic endothelial cells from a patient with lymphatic malformation[J]. Angiogenesis, 2015, 18(2): 151-162.
[13] 赵怡芳, 刘斌, 张文峰. 口腔颌面部淋巴管畸形的VEGF-C和VEGFR-3表达 [J]. 口腔医学研究, 2004, 20(4): 389-391.
[14] Cai X, Zhang W, Chen G, et al. Mesenchymal status of lymphatic endothelial cell: enlightening treatment of lymphatic malformation [J]. Int J Clin Exp Med, 2015, 8(8): 12239-12251.
[15] Dhariwal AK, Bavdekar SB. Sildenafil in pediatric pulmonary arterial hypertension [J]. J Postgrad Med, 2015, 61(3): 181-192.
[16] Wu JK, Kitajewski C, Reiley M, et al. Aberrant lymphatic endothelial progenitors in lymphatic malformation development [J]. PLoS One, 2015, 10(2): e0117352.
[17] Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics [J]. Plast Reconstr Surg, 1982, 69(3): 412-422.
[18] Secker GA, Harvey NL. VEGFR signaling during lymphatic vascular development: from progenitor cells to functional vessels [J]. Dev Dyn, 2015, 244(3): 323-331.